In therapeutic cancer trials, high-dose IL-2 (>50 Million International Units (MIU)/8 hours) [36] stimulates Teffs to attack cancer cells [37], whereas in low-dose IL-2 therapy (<6 MIU/day) [36] for autoimmune diseases, Tregs are stimulated [38]. The gene discussed is IL2; the disease is cancer.